Lantheus Reports Fourth Quarter and Full Year 2023 Financial Results
February 22, 2024 07:00 ET
|
Lantheus Holdings, Inc.
Worldwide revenue of $354.0 million and $1.3 billion for the fourth quarter and full year 2023GAAP net income of $103.4 million and $326.7 million for the fourth quarter and full year 2023GAAP fully...
Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging
February 13, 2024 08:30 ET
|
Lantheus Holdings, Inc.
Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ:...
Lantheus to Host Fourth Quarter and Full Year 2023 Earnings Conference Call and Webcast on February 22, 2024, at 8:00 a.m. Eastern Time
February 08, 2024 08:00 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday,...
Lantheus Announces CEO Succession Plan
January 23, 2024 07:45 ET
|
Lantheus Holdings, Inc.
Lantheus Board Member and Pharmaceutical Industry Veteran Brian Markison Appointed Lantheus Chief Executive Officer, Effective March 1, 2024 Mary Anne Heino to Retire as Chief Executive Officer and...
Lantheus Announces Acceptance of its First-to-File ANDA for Generic LUTATHERA® (Lutetium Lu 177 Dotatate)
January 11, 2024 08:00 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling...
Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
January 09, 2024 08:00 ET
|
Lantheus Holdings, Inc.
Option to license Perspective Therapeutics’ Pb212-VMT-α-NET asset Co-development rights for certain Pb212-based alpha therapies for prostate cancer Equity investment of up to 19.9% in Perspective...
Lantheus Reports Preliminary Fiscal Year 2023 Revenue
January 09, 2024 07:55 ET
|
Lantheus Holdings, Inc.
Full year 2023 worldwide revenue expected to be in the range of $1.295 – 1.297 billion, a 38 - 39% increase over the prior year including a $15 million RELISTOR milestone achievement Full year 2023...
Lantheus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...
Lantheus and POINT Biopharma Announce Positive Topline Results from Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
December 18, 2023 07:30 ET
|
Lantheus Holdings, Inc.
Phase 3 SPLASH study of 177Lu-PNT2002 demonstrated statistically significant improvement in radiographic progression-free survival (rPFS) BEDFORD, Mass., and INDIANAPOLIS, Dec. 18, 2023 ...
Lantheus to Present at the Jefferies London Healthcare Conference
November 08, 2023 08:00 ET
|
Lantheus Holdings, Inc.
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight...